HSV-1 gD Inhibitors
The class of HSV-1 gD inhibitors comprises a diverse range of chemicals that directly or indirectly target the viral protein gD, a critical component of the herpes simplex virus type 1 (HSV-1). One approach involves direct inhibition of viral replication, exemplified by nucleoside analogs like Cidofovir and Acyclovir. These compounds act as inhibitors of HSV-1 DNA polymerase, disrupting viral DNA synthesis and ultimately reducing the production of gD. This highlights the efficacy of targeting viral components to attenuate the expression and function of specific viral proteins, such as gD. Additionally, indirect inhibitors like BX795 and BAY-2402234 exemplify a strategic approach by targeting host cellular processes. BX795 disrupts the STING-mediated antiviral response, indirectly impacting gD expression by modulating interferon pathways. On the other hand, BAY-2402234, a USP7 inhibitor, influences gD by disrupting the deubiquitination of host factors, emphasizing the ability of targeting host cellular processes to modulate viral protein activity. These examples showcase the versatility of inhibitors within this class, providing multiple avenues for intervention.
Furthermore, metabolic inhibitors such as 2-Deoxy-D-glucose highlight the ability to alter cellular energy production to impact viral replication and subsequently inhibit gD expression. Similarly, signaling pathway inhibitors like SP600125 and Ruxolitinib demonstrate the importance of host cell signaling cascades, offering indirect means to regulate gD expression. This chemical class's diversity underscores the complexity of host-virus interactions and provides a rich landscape for investigating antiviral strategies targeting HSV-1 gD.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX795, an inhibitor of TBK1/IKKε, indirectly impacts HSV-1 gD by disrupting the STING-mediated antiviral response. By inhibiting TBK1/IKKε, BX795 modulates the interferon pathway, leading to the downregulation of antiviral factors that would otherwise suppress HSV-1 gD expression and function. This compound highlights the interconnectedness of host cellular pathways in regulating viral proteins. | ||||||
Cidofovir | 113852-37-2 | sc-482141 | 50 mg | $135.00 | ||
Cidofovir, an acyclic nucleoside phosphonate analog, acts as a direct inhibitor of HSV-1 DNA polymerase, disrupting viral DNA synthesis. By impeding viral replication, Cidofovir indirectly reduces the production of HSV-1 gD. Its antiviral mechanism emphasizes the importance of targeting viral components to impact the expression and function of specific viral proteins like gD. | ||||||
Acyclovir | 59277-89-3 | sc-202906 sc-202906A | 50 mg 500 mg | $150.00 $940.00 | 2 | |
Acyclovir, a guanosine analog, is phosphorylated by viral thymidine kinase and inhibits HSV-1 DNA polymerase, suppressing viral DNA synthesis. Through its action on viral replication, Acyclovir indirectly hinders the expression of HSV-1 gD. This compound showcases the significance of disrupting viral processes to modulate the levels and activity of specific viral proteins. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose, an analog of glucose, indirectly inhibits HSV-1 gD by disrupting glycolysis. As a metabolic inhibitor, 2-Deoxy-D-glucose alters cellular energy production, impacting the host cell's ability to support efficient viral replication, which consequently affects the expression and function of HSV-1 gD. This compound highlights the potential of metabolic interventions in modulating viral protein activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a selective JNK inhibitor, indirectly influences HSV-1 gD by suppressing the JNK signaling pathway. By inhibiting JNK, SP600125 disrupts cellular signaling events that may otherwise support HSV-1 gD expression and function. This compound illustrates the intricate connection between host cellular pathways and the regulation of specific viral proteins, offering insights into potential antiviral strategies. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, indirectly impacts HSV-1 gD by modulating the JAK-STAT signaling pathway. Through JAK inhibition, Ruxolitinib alters host cell responses that could contribute to HSV-1 gD expression and function. This compound exemplifies the potential of targeting host signaling pathways to indirectly regulate viral protein activity, providing avenues for antiviral intervention. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $96.00 $264.00 | 2 | |
Ionomycin, a calcium ionophore, indirectly inhibits HSV-1 gD by disrupting calcium-dependent cellular processes. By altering calcium signaling, Ionomycin influences host cell functions that support HSV-1 gD expression and function. This compound underscores the importance of host cell calcium dynamics in regulating viral protein activity and provides insights into potential antiviral strategies. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1, a vacuolar ATPase inhibitor, indirectly impacts HSV-1 gD by modulating endosomal acidification. By inhibiting vacuolar ATPase, Bafilomycin A1 disrupts the endocytic pathway, potentially influencing the intracellular trafficking of HSV-1 gD and its expression. This compound highlights the relevance of cellular trafficking processes in regulating viral protein activity. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $39.00 $59.00 $104.00 $206.00 | 8 | |
Geldanamycin, an Hsp90 inhibitor, indirectly influences HSV-1 gD by disrupting protein folding and stability. By targeting Hsp90, Geldanamycin alters the chaperone-mediated maturation of cellular and viral proteins, potentially impacting the expression and function of HSV-1 gD. This compound exemplifies the intricate interplay between cellular protein homeostasis and viral protein activity. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $29.00 $90.00 $339.00 | 12 | |
Lovastatin, an HMG-CoA reductase inhibitor, indirectly inhibits HSV-1 gD by impacting cholesterol biosynthesis. By modulating cholesterol levels, Lovastatin alters membrane composition, potentially influencing the localization and function of HSV-1 gD. | ||||||